Skip to content
PubMed This is a summary of 6 peer-reviewed journal articles Updated
Infectious Disease · Immunodeficiency 107

Managing a Crisis: Treatment for Acute Episodes and Tissue Necrosis

At a Glance

In IMD107, a severe Staphylococcus aureus infection can cause tissue necrosis that may continue even after the bacteria are killed. Urgent IV antibiotics, cultures, removal of dead tissue, and specialist care are priorities; immune-calming drugs are experimental.

When a person with Immunodeficiency 107 (IMD107) experiences an acute episode, the treatment approach must be aggressive and specialized. It is completely normal to feel frightened during a medical crisis, but knowing that a clear strategy exists can provide reassurance. Because the condition creates a specific “hidden” vulnerability in your tissues, standard home care for a “Staph” infection is not enough. Treatment usually involves a two-part strategy: clearing the bacteria and stopping the progressive tissue damage [1][2].

The Essential First Step: Antibiotics and Surgery

If you are hospitalized for a suspected IMD107-related infection, the medical team will immediately focus on source control—meaning they must find and stop the infection at its root [2].

  • Aggressive Antibiotics: Doctors will use powerful, broad-spectrum or anti-staphylococcal antibiotics (given through an IV) to kill the S. aureus bacteria and prevent it from spreading to your blood or lungs [3][4]. The choice depends on cultures, local resistance, and allergies.
  • Surgical Debridement: If necrosis (tissue death) has already begun, devitalized tissue has poor blood supply and can harbor infection, so antibiotics alone cannot resolve the issue. A surgeon may need to perform debridement, which is the medical removal of dead, damaged, or infected tissue to allow the surrounding healthy tissue to heal [4].

Why Antibiotics Might Not Be Enough

A critical, and often confusing, fact about IMD107 is that antibiotics alone may fail to stop the tissue damage [3].

Even after the bacteria are killed, the toxins they left behind (like alpha-toxin) and the body’s own inflammatory response can continue to severely injure your skin or lung cells [1][3]. Patients have had cases where their fever went away and their blood tests improved, yet their wounds continued to grow larger and more necrotic [3].

Halting Tissue Death: Immunomodulators

If the necrosis continues to spread despite antibiotics and surgery, your doctors may consider specialized treatments to “calm” the immune system’s destructive response. These are strictly experimental or off-label options reported only in exceptional cases; they are not an established IMD107 protocol or a standard escalation pathway [3][4]:

  • TNF Inhibitors (e.g., Infliximab): These medications block a specific protein called TNF that drives inflammation. In some documented IMD107 patients, starting infliximab led to prompt improvement and healing of wounds that had been worsening for weeks [3][4].
  • Glucocorticoids (Steroids): High-dose steroids may be used alongside TNF inhibitors to quickly reduce the inflammatory “fire” in the affected tissues [3][5].

Important Note: Using these “immune-calming” drugs during an active infection is a complex decision that must be managed by an expert multidisciplinary team, including Infectious Disease and Immunology specialists [3]. The team must balance the risk of inflammatory tissue injury against the severe danger of worsening an uncontrolled active infection. Urgent surgical source control, cultures, and appropriate antibiotics remain the absolute priorities.

Long-Term Prevention and Maintenance

Unlike many other primary immunodeficiencies, there is currently no established routine protocol for daily prophylactic (preventative) antibiotics or immunoglobulin replacement (IVIG/SCIG) for IMD107 [1][6].

This is because your blood-based immune system—the part that IVIG helps—is typically unaffected [1]. Instead of a blanket standard requiring daily medication, the care for IMD107 emphasizes individualized decision making:

  1. Immediate Hospitalization: Seeking expert care at the very first sign of a severe infection or necrotic wound [2].
  2. Specialist Oversight: Ensuring that an immunologist and an infectious disease expert are part of your permanent care team to manage your specific risk profile. Decisions regarding preventative antibiotics should be made case by case based on recurrent infections, colonization, and antibiotic stewardship [3].
  3. Toxin Awareness: Understanding that the goal is not just to kill “Staph,” but to protect your tissues from the toxins that the bacteria produce [1].

By focusing on rapid, expert intervention and individualized care rather than relying solely on daily preventative drugs, patients and doctors can effectively manage the unique risks of this rare condition.

Common questions in this guide

How is a serious Staph infection treated in someone with IMD107?
A suspected serious infection generally needs urgent hospital care, tests to identify the bacteria, intravenous antibiotics that target Staphylococcus aureus, and evaluation for infection source control. If dead or infected tissue is present, surgery may be needed because antibiotics alone may not reach it effectively.
Why can tissue damage continue after antibiotics start working?
Bacterial toxins left in the tissue and the body’s inflammatory response can continue injuring skin or lung cells after treatment begins. A wound may worsen even when fever and blood tests improve, so clinicians must assess the tissue itself.
What wound changes mean an IMD107 patient needs urgent surgical assessment?
A wound that changes color, blisters, enlarges, or shows signs of tissue death should be assessed urgently, especially when a Staphylococcus aureus infection is suspected. A surgeon determines whether dead, damaged, or infected tissue must be removed to control the infection.
Are infliximab or steroids routine treatments for IMD107?
No. Infliximab and high-dose steroids have been used only in exceptional, experimental, or off-label situations when tissue damage continues despite antibiotics and surgery. Because they can worsen an uncontrolled infection, their use requires close coordination among infectious disease, immunology, and surgical specialists.
Does everyone with IMD107 need daily preventive antibiotics or IVIG?
There is no established routine recommendation for daily preventive antibiotics or immunoglobulin replacement for IMD107. The blood-based immune system that immunoglobulin replacement supports is typically unaffected, so specialists decide case by case using the person’s infection history, bacterial test results, and treatment risks.
Which specialists should be involved during an IMD107 infection?
Acute care should involve infectious disease and immunology specialists, with surgery involved when tissue damage or necrosis is suspected. The hospital team can coordinate antibiotics, bacterial testing, removal of dead tissue, and decisions about any experimental immune-calming treatment.
Can normal blood tests rule out serious tissue damage in IMD107?
No. A wound can continue to enlarge or become necrotic even after fever and routine blood tests improve, so the appearance and progression of the tissue matter. Report new color changes, blisters, or worsening wounds urgently.

Get notified when new evidence is published on immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin.

    Spaan AN, Neehus AL, Laplantine E, et al.

    Science (New York, N.Y.) 2022; (376(6599)):eabm6380 doi:10.1126/science.abm6380.

    PMID: 35587511
  2. 2

    Novel genotypes, phenotypes, and triggers in humans with OTULIN haploinsufficiency.

    van der Linden TJ, Arts RJW, Biggs CM, et al.

    Journal of human immunity 2025; (1(4)) doi:10.70962/jhi.20250018.

    PMID: 41293556
  3. 3

    Failure to Close: An Unexpected Surgical Complication Reveals OTULIN Haploinsufficiency.

    Nguyen J, Kim CF, Ramirez AA, Vogel TP

    ACR open rheumatology 2025; (7(3)):e11800 doi:10.1002/acr2.11800.

    PMID: 40084498
  4. 4

    OTULIN Haploinsufficiency-Related Fasciitis and Skin Necrosis Treated by TNF Inhibition.

    Arts RJW, van der Linden TJ, van der Made CI, et al.

    Journal of clinical immunology 2023; (44(1)):10 doi:10.1007/s10875-023-01630-4.

    PMID: 38129331
  5. 5

    New data in causes of autoinflammatory diseases.

    Kone-Paut I, Georgin-Laviallec S, Galeotti C, et al.

    Joint bone spine 2019; (86(5)):554-561 doi:10.1016/j.jbspin.2018.11.003.

    PMID: 30471422
  6. 6

    OTULIN haploinsufficiency predisposes to environmentally directed inflammation.

    Staels F, Bücken L, De Vuyst L, et al.

    Frontiers in immunology 2024; (15()):983686 doi:10.3389/fimmu.2024.983686.

    PMID: 38827742

This page explains emergency treatment considerations for IMD107 and tissue necrosis for informational purposes only; it does not replace medical advice. Seek urgent care and follow your infectious disease, immunology, and surgical teams for a suspected infection.